

October 23, 2025

|                                                                                                                                                                                                   |                                                                                                                                                                                   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| To<br>Listing Department,<br><b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b><br>Exchange Plaza,<br>Bandra Kurla Complex, Bandra (E),<br>MUMBAI -400 051<br><br><b>Company Code No. AUROPHARMA</b> | To<br>The Corporate Relations Department<br><b>BSE LIMITED</b><br>Phiroz Jeejeebhoy Towers,<br>25th floor, Dalal Street,<br>MUMBAI -400 001<br><br><b>Company Code No. 524804</b> |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Dear Sir / Madam,

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

This is to inform you that Helix Healthcare B.V, a wholly owned subsidiary of the Company, has incorporated a new wholly owned subsidiary in Chile by the name of **Aurobindo Pharma Chile SpA**.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as '**Annexure A**'.

This is for your information and records.

Yours faithfully,  
**For AUROBINDO PHARMA LIMITED**

**B. Adi Reddy**  
**Company Secretary**

Enclosures: Annexure A

**AUROBINDO PHARMA LIMITED**

[www.aurobindo.com](http://www.aurobindo.com)

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.  
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad-500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833  
Email: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)

### Annexure -A

#### Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

|                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                              |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| a) Name of the target entity, details in brief such as size, turnover etc.;                                                                                                                                                                                                         | Name: Aurobindo Pharma Chile SpA<br>Turnover: Not applicable as the company was incorporated on October 7, 2025.                                                                                                                                                             |
| b) Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length"; | Aurobindo Pharma Chile SpA is incorporated as a wholly owned subsidiary of Helix Healthcare B.V, a wholly owned subsidiary of the Company and therefore is a related party of the Company. Promoters and promoter group of the Company are not interested in the transaction |
| c) Industry to which the business of the target entity being acquired belongs;                                                                                                                                                                                                      | Pharmaceuticals                                                                                                                                                                                                                                                              |
| d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);                                                                            | The object of incorporation of this wholly owned subsidiary is to expand the Pharmaceutical Products business in Chile.                                                                                                                                                      |
| e) Brief details of any governmental or regulatory approvals required for the acquisition.                                                                                                                                                                                          | No governmental or regulatory approvals required.                                                                                                                                                                                                                            |
| f) Indicative time period for completion of the acquisition.                                                                                                                                                                                                                        | Not applicable                                                                                                                                                                                                                                                               |
| g) Nature of consideration - whether cash consideration or share swap or any other form and details of the same;                                                                                                                                                                    | 100% subscription to the share capital in cash                                                                                                                                                                                                                               |
| h) Cost of acquisition and / or the price at which the shares are acquired; <b>New Subsidiary was incorporated.</b>                                                                                                                                                                 | Initial subscription to the share capital of CLP 1,000,000 (USD _1050) divided into 100 shares with a nominal value of CLP 10,000 each                                                                                                                                       |
| i) Percentage of shareholding / control acquired and or number of shares acquired;                                                                                                                                                                                                  | 100%                                                                                                                                                                                                                                                                         |
| j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);                          | This is a newly incorporated company and therefore the history of the last 3 years' turnover is not available.<br><br>Date of Incorporation is October 7, 2025 and received the signed formation documents on October 22, 2025.                                              |

## AUROBINDO PHARMA LIMITED

[www.aurobindo.com](http://www.aurobindo.com)

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.  
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad -500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833  
Email: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)